Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and p

Trial Details

NCT ID

NCT07172386

Phase

PHASE2

Sponsor

Tianjin Medical University Second Hospital

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

• Toripalimab and axitinib

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Willing and able to provide written informed consent
• Age ≥ 18 years
• Patients with pathologically and radiographically confirmed renal cell carcinoma:
• cT2N0M0 with Grade 4 or sarcomatoid feature;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →